News

/News/

NICE evidence request for Blincyto for acute lymphoblastic leukaemia

The National Institute for Health and Care Excellence (NICE) has requested further evidence on Amgen’s Blincyto (blinatumomab) for the treatment of adults with acute lymphoblastic leukaemia.

The committee concluded that Blincyto has significant clinical benefits, but that further evidence on cost-effectiveness is required to assess its plausibility for NHS funding. NICE has requested further clarification from the company for the second committee meeting in April.

Read the full article by Anna Smith here.

By |2019-03-20T15:57:10+00:00March 7th, 2019|News|0 Comments

NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access

NHS England now plays a key market access gatekeeper role for the industry’s high cost specialised medicines, and has become increasingly commercially savvy over the last few years, working alongside cost effectiveness watchdog NICE.

Late last year, NHS England went one step further to develop its pricing and reimbursement expertise and appointed Blake Dark, an experienced pharma industry executive, as the new head of its commercial medicines division.

Read the full PMLive article here

By |2019-03-20T15:58:11+00:00March 6th, 2019|News|0 Comments

NICE recommends Pertuzumab for treatment of early breast cancer

The United Kingdom’s National Institute for Health and Care Excellence (NICE) today released a final appraisal of pertuzumab (Perjeta) together with intravenous trastuzumab and chemotherapy for the treatment of HER2-positive early breast cancer, and recommended pertuzumab for use in patients if they have lymph node–positive disease and if drug maker Roche adheres to its promised discount for the drug.

NICE’s final appraisal indicates that Roche has offered the National Health Service (NHS) a discount on the drug, which carries a UK list price of £2395 (approximately $3068) per 420-mg vial. That discount, taken together with the cost savings made possible by biosimilar trastuzumab agents that have recently entered the UK market, brings the cost-effectiveness estimate for the therapy per quality-adjusted life-year (QALY) gained to “comfortably below £20,000,” or below approximately $25,627, which is NICE’s typical cost-effectiveness threshold.

Read the full article by The Center for Biosimilars Staff here

By |2019-03-20T16:02:18+00:00March 1st, 2019|News|0 Comments

Faster patient access in France – can the Government deliver on its new pricing and market access timelines?

The French Government has recently announced initiatives to reduce the time taken for patients to gain access to new drugs. At the Strategic Council of Health Industries (CSIS) in July 2018, the French Prime Minister Edouard Philippe announced the Government’s plans to reduce delays in pricing and market access for new drugs, as well as new indications for existing drugs. Philippe Lamoureux, the Director of LEEM (the French pharmaceutical industry association) described this as the most important CSIS since 2009 due to President Macron’s clear affirmation of his pro-business vision for the French healthcare system. In addition to implementing fast-track schemes for clinical trials of new drugs, the French Government’s plans to accelerate pricing and reimbursement can be divided into two main areas:

1. Improving adherence to the official 180-day market access timelines
2. Expanding and streamlining the Temporary Authorisation for Use (ATU) scheme.

Improving adherence to the official 180-day market access […]

By |2019-03-20T16:04:39+00:00February 27th, 2019|News|0 Comments

Remap Consulting are official META Tool facilitators with NICE

Remap Consulting are certified by NICE as a META Tool facilitating organisation. As trained facilitators, we can help companies understand what payer evidence is required to demonstrate the value of their healthcare technologies.

The META Tool is an online service that helps medical technology developers optimise their development plans for their medical technology.

Further information on how Remap Consulting can assist with UK patient access for your MedTech product can be found here.

By |2019-03-20T16:07:51+00:00February 14th, 2019|News|0 Comments